Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1955 1
1961 3
1962 6
1963 2
1964 1
1965 2
1966 4
1967 1
1968 8
1969 3
1970 14
1971 14
1972 13
1973 6
1974 8
1975 11
1976 17
1977 15
1978 6
1979 11
1980 6
1981 12
1982 22
1983 16
1984 16
1985 18
1986 25
1987 40
1988 27
1989 45
1990 20
1991 38
1992 35
1993 48
1994 47
1995 56
1996 56
1997 72
1998 46
1999 44
2000 56
2001 75
2002 70
2003 80
2004 55
2005 65
2006 59
2007 70
2008 66
2009 66
2010 82
2011 70
2012 87
2013 75
2014 88
2015 94
2016 98
2017 119
2018 102
2019 90
2020 109
2021 133
2022 115
2023 103
2024 79

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,730 results

Results by year

Filters applied: . Clear all
Page 1
Japanese guidelines for atopic dermatitis 2020.
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, Shimojo N, Tanaka A, Nakahara T, Nagao M, Hide M, Fujita Y, Fujisawa T, Futamura M, Masuda K, Murota H, Yamamoto-Hanada K; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2018, The Japanese Society of Allergology, The Japanese Dermatology Association. Katoh N, et al. Among authors: masuda k. Allergol Int. 2020 Jul;69(3):356-369. doi: 10.1016/j.alit.2020.02.006. Epub 2020 Apr 4. Allergol Int. 2020. PMID: 32265116 Free article. Review.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Klümpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators. Goyal L, et al. Among authors: masuda k. N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834. N Engl J Med. 2023. PMID: 36652354 Clinical Trial.
Regulation of IL-6 in Immunity and Diseases.
Tanaka T, Narazaki M, Masuda K, Kishimoto T. Tanaka T, et al. Among authors: masuda k. Adv Exp Med Biol. 2016;941:79-88. doi: 10.1007/978-94-024-0921-5_4. Adv Exp Med Biol. 2016. PMID: 27734409 Review.
Beta-blockade enhances anthracycline control of metastasis in triple-negative breast cancer.
Chang A, Botteri E, Gillis RD, Löfling L, Le CP, Ziegler AI, Chung NC, Rowe MC, Fabb SA, Hartley BJ, Nowell CJ, Kurozumi S, Gandini S, Munzone E, Montagna E, Eikelis N, Phillips SE, Honda C, Masuda K, Katayama A, Oyama T, Cole SW, Lambert GW, Walker AK, Sloan EK. Chang A, et al. Among authors: masuda k. Sci Transl Med. 2023 Apr 26;15(693):eadf1147. doi: 10.1126/scitranslmed.adf1147. Epub 2023 Apr 26. Sci Transl Med. 2023. PMID: 37099632
CD153/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury.
Sato Y, Oguchi A, Fukushima Y, Masuda K, Toriu N, Taniguchi K, Yoshikawa T, Cui X, Kondo M, Hosoi T, Komidori S, Shimizu Y, Fujita H, Jiang L, Kong Y, Yamanashi T, Seita J, Yamamoto T, Toyokuni S, Hamazaki Y, Hattori M, Yoshikai Y, Boor P, Floege J, Kawamoto H, Murakawa Y, Minato N, Yanagita M. Sato Y, et al. Among authors: masuda k. J Clin Invest. 2022 Jan 18;132(2):e146071. doi: 10.1172/JCI146071. J Clin Invest. 2022. PMID: 34813503 Free PMC article.
English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021.
Saeki H, Ohya Y, Furuta J, Arakawa H, Ichiyama S, Katsunuma T, Katoh N, Tanaka A, Tsunemi Y, Nakahara T, Nagao M, Narita M, Hide M, Fujisawa T, Futamura M, Masuda K, Matsubara T, Murota H, Yamamoto-Hanada K. Saeki H, et al. Among authors: masuda k. J Dermatol. 2022 Oct;49(10):e315-e375. doi: 10.1111/1346-8138.16527. Epub 2022 Aug 22. J Dermatol. 2022. PMID: 35996152
SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.
Lu Z, Mao W, Yang H, Santiago-O'Farrill JM, Rask PJ, Mondal J, Chen H, Ivan C, Liu X, Liu CG, Xi Y, Masuda K, Carrami EM, Chen M, Tang Y, Pang L, Lakomy DS, Calin GA, Liang H, Ahmed AA, Vankayalapati H, Bast RC Jr. Lu Z, et al. Among authors: masuda k. J Clin Invest. 2022 Jun 1;132(11):e146471. doi: 10.1172/JCI146471. J Clin Invest. 2022. PMID: 35642638 Free PMC article.
Multiplexed single-cell analysis reveals prognostic and nonprognostic T cell types in human colorectal cancer.
Masuda K, Kornberg A, Miller J, Lin S, Suek N, Botella T, Secener KA, Bacarella AM, Cheng L, Ingham M, Rosario V, Al-Mazrou AM, Lee-Kong SA, Kiran RP, Stoeckius M, Smibert P, Del Portillo A, Oberstein PE, Sims PA, Yan KS, Han A. Masuda K, et al. JCI Insight. 2022 Apr 8;7(7):e154646. doi: 10.1172/jci.insight.154646. JCI Insight. 2022. PMID: 35192548 Free PMC article.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: masuda k. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
2,730 results